MedTrace Logo

Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC

NCT04144608 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-08-09

No results posted yet for this study

Summary

The aim of the study was to investigate the efficacy of Toripalimab Combined with Double Platinum Based Chemotherapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer.

Conditions

  • Advanced Non Small Cell Lung Cancer

Interventions

DRUG

Toripalimab

Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1

Sponsors & Collaborators

  • Yongchang Zhang

    lead OTHER

Principal Investigators

  • Yongchang Z MD, MD · Hunan Province Tumor Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-16
Primary Completion
2022-06-30
Completion
2023-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04144608 on ClinicalTrials.gov